Logotype for ALX Oncology Holdings Inc

ALX Oncology (ALXO) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ALX Oncology Holdings Inc

Q3 2026 earnings summary

16 Nov, 2026

Executive summary

  • Clinical-stage pipeline centers on evorpacept and ALX2004; no product revenue has been generated, and net losses are expected to continue.

  • Q3 GAAP net loss was $21.8M; 9M net loss was $57.7M, down from $78.8M in 9M 2025.

  • Cash, cash equivalents and investments totaled $147.2M at Sept. 30, 2026, supporting a projected operating runway through H1 2028.

Financial highlights

  • Q3 operating expenses were $22.9M vs. $22.5M YoY; 9M expenses were $59.9M vs. $81.0M.

  • Q3 R&D was $17.5M vs. $17.4M YoY; 9M R&D declined 26% to $44.2M, primarily due to fewer active trials, pipeline prioritization and reduced workforce costs.

  • Q3 G&A rose 8% to $5.5M from $5.1M; 9M G&A fell 14% to $16.0M.

  • Q3 loss per basic and diluted share was $0.15 vs. $0.41; 9M loss per share was $0.45 vs. $1.48.

  • Q3 non-GAAP net loss was $18.9M vs. $19.6M; 9M non-GAAP net loss was $48.6M vs. $65.6M.

Outlook and guidance

  • Existing cash, cash equivalents and investments are expected to fund planned operations through H1 2028; actual cash use could exceed estimates.

  • Topline ASPEN-09-Breast data from 120 patients are expected in 2H 2027.

  • ALX2004 Phase 1 safety and early efficacy results from 35 enrolled patients are expected in December 2026.

  • Significant expenses and increasing operating losses are expected as evorpacept and ALX2004 advance through clinical development, manufacturing and pre-commercial work; additional capital will be needed to fully implement the business plan.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ALX Oncology